# Laura E. Benjamin

> Laura E. Benjamin is the CEO and President of Myris Therapeutics, a Pittsburgh-based biotech building ultra-high DAR antibody-drug conjugates that fuse polymer chemistry with cancer biologics. A molecular biologist by training, she has moved from Harvard pathology labs to Eli Lilly oncology leadership to two CEO chairs - most recently steering OncXerna through more than $100 million in clinical-stage financing before taking the helm at Myris in 2024.

- **Role:** CEO and President at Myris Therapeutics
- **Organizations:** Myris Therapeutics, BioHybrid Solutions, OncXerna Therapeutics, Eli Lilly and Company, Harvard Medical School, Beth Israel Deaconess Medical Center
- **Nationality:** American
- **Education:** B.A., Biology, Barnard College, Columbia University, Ph.D., Molecular Biology, University of Pennsylvania
- **Known for:** Raised more than $100 million at OncXerna Therapeutics to advance two clinical oncology programs, Led Myris Therapeutics out of stealth in February 2025 with a polymer-enabled ADC platform, Developed ADC technology capable of DAR ratios of 50-300, an order of magnitude beyond current clinical ADCs

## Career timeline

- **early career** — Associate Professor in Pathology at Harvard Medical School; Co-director of the Center for Vascular Biology at Beth Israel Deaconess Medical Center
- **pre-2018** — VP / Chief Scientific Officer in oncology at Eli Lilly
- **2018** — Became CEO and President of OncXerna Therapeutics
- **2023-06** — Appointed to the BioHybrid Solutions Board of Directors as executive chairperson
- **2023-08** — Ended tenure as CEO of OncXerna Therapeutics
- **2024** — Stepped in as CEO and President of Myris Therapeutics (formerly BioHybrid Solutions)
- **2025-02** — Led Myris Therapeutics out of stealth with ultra-high DAR ADC platform
- **2025-04** — First public scientific presentation at AACR Annual Meeting in Chicago

## Achievements

- Raised more than $100 million at OncXerna Therapeutics to advance two clinical oncology programs
- Led Myris Therapeutics out of stealth in February 2025 with a polymer-enabled ADC platform
- Developed ADC technology capable of DAR ratios of 50-300, an order of magnitude beyond current clinical ADCs
- Held senior scientific roles at Eli Lilly (oncology), Harvard Medical School, and Beth Israel Deaconess
- Published research career spanning cancer biology and vascular biology

## Latest updates

- **2025-02** — Myris Therapeutics emerged from stealth, announcing its ultra-high DAR ADC platform.
- **2025-04** — Myris presented its platform publicly for the first time at the AACR Annual Meeting in Chicago.
- **2026-06** — Scheduled to appear in a fireside chat with Force Family Office on Myris's market positioning.

## Links

- Website: https://myristx.com
- LinkedIn: https://www.linkedin.com/in/laura-e-benjamin-04299b34

---

Profile page: https://yespress.io/laura-benjamin
Published by YesPress — https://yespress.io
Last updated: 2026-06-30